Fractional excretion of IgG in idiopathic membranous nephropathy with nephrotic syndrome: A predictive marker of risk and drug responsiveness

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Bazzi, Claudio ^a   Rizza, Virginia ^b   Casellato, Daniela ^b   Tofik, Rafid ^c   Berg, Anna Lena ^c   Gallieni, Maurizio ^b   D'Amico, Giuseppe ^a   Bakoush, Omran ^c,d  

^a D'Amico Foundation for Renal Diseases Research   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

^c LUND UNIVERSITY   (Sweden)

^d UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Albuminuria; Cyclophosphamide; ESRD; Idiopathic membranous glomerulonephritis; Immunoglobulin G; Nephrotic syndrome; Proteinuria; Steroids; Treatment outcome

Indexed keywords

ALPHA 1 MICROGLOBULIN; CORTICOTROPIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; BIOLOGICAL MARKER; URINARY TRACT AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; IDIOPATHIC MEMBRANOUS NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MICROALBUMINURIA; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROSPECTIVE STUDY; REMISSION; RISK FACTOR; TREATMENT RESPONSE; URINARY EXCRETION; CLINICAL TRIAL; GLOMERULONEPHRITIS, MEMBRANOUS; MIDDLE AGED; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; URINE;

BIOLOGICAL MARKERS; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PROSPECTIVE STUDIES; RENAL AGENTS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84900875533     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-74     Document Type: Article

References (28)

1. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Haas M, Meehan SM, Karrison TG, Spargo BH, Am J Kidney Dis 1997 30 5 621 631 10.1016/S0272-6386(97) 90485-6 9370176
2. The increased risk of coronary heart disease associated with nephrotic syndrome. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH, Kidney Int 1993 44 3 638 642 10.1038/ki.1993.292 8231039
3. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ, N Engl J Med 2009 361 1 11 21 10.1056/NEJMoa0810457 19571279
4. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R, J Am Soc Nephrol 1998 9 3 444 450 9513907
5. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi C, Pozzi C, Bizzarri D, Banfi G, Kidney Int 1995 48 5 1600 1604 10.1038/ki.1995.453 8544420
6. Prognosis of untreated patients with idiopathic membranous nephropathy. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G, N Engl J Med 1993 329 2 85 89 10.1056/NEJM199307083290203 8510707
7. Nonimmunosuppressive therapy of membranous nephropathy. Schieppati A, Ruggenenti P, Perna A, Remuzzi G, Semin Nephrol 2003 23 4 333 339 10.1016/S0270-9295(03)00050-0 12923721
8. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. Branten AJ, Reichert LJ, Koene RA, Wetzels JF, QJM 1998 91 5 359 366 10.1093/qjmed/91.5.359 9709470
9. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. du Buf-Vereijken PW, Branten AJ, Wetzels JF, Membranous Nephropathy Study G, Nephrol Dial Transplant 2004 19 5 1142 1148 10.1093/ndt/gfh036 14993502
10. The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum? Glassock RJ, Am J Kidney Dis 2004 44 3 562 566 10.1053/j.ajkd.2004. 06.003 15332231
11. Management of membranous nephropathy: when and what for treatment. Cattran D, J Am Soc Nephrol 2005 16 5 1188 1194 10.1681/ASN.2005010028 15800117
12. A new equation to estimate glomerular filtration rate. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collab, Ann Intern Med 2009 150 9 604 612 10.7326/0003-4819-150-9-200905050- 00006 19414839
13. The value of IgG-uria in predicting renal failure in idiopathic glomerular diseases. A long-term follow-up study. Tofik R, Aziz R, Reda A, Rippe B, Bakoush O, Scand J Clin Lab Invest 2011 71 2 123 128 21133834
14. Urine IgM-excretion as a prognostic marker for progression of type 2 diabetic nephropathy. Tofik R, Torffvit O, Rippe B, Bakoush O, Diabetes Res Clin Pract 2012 95 1 139 144 10.1016/j.diabres.2011.10.008 22078636
15. Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Bazzi C, Petrini C, Rizza V, Arrigo G, Beltrame A, Pisano L, D'Amico G, Am J Kidney Dis 2001 38 2 240 248 10.1053/ajkd.2001.26080 11479148
16. Fractional excretion of IgG predicts renal outcome and response to therapy in primary focal segmental glomerulosclerosis: a pilot study. Bazzi C, Petrini C, Rizza V, Napodano P, Paparella M, Arrigo G, Pisano L, D'Amico G, Am J Kidney Dis 2003 41 2 328 335 10.1053/ajkd.2003.50040 12552493
17. Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. Branten AJ, du Buf-Vereijken PW, Klasen IS, Bosch FH, Feith GW, Hollander DA, Wetzels JF, J Am Soc Nephrol 2005 16 1 169 174 15563570
18. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Irazabal MV, Eirin A, Lieske J, Beck LH, Sethi S, Borland TM, Dillon JJ, Nachman PH, Nasr SH, Cornell LD, Leung N, Cattran DC, Fervenza FC, Nephrol Dial Transplant 2013 28 1 137 146 10.1093/ndt/gfs379 22987142
19. Urinary concentration of monocyte chemoattractant protein-1 in idiopathic glomerulonephritis: a long-term follow-up study. Tofik R, Ohlsson S, Bakoush O, PLoS One 2014 9 1 87857 10.1371/journal.pone.0087857 24489972
20. The more things change. Wasserstein AG, Am J Kidney Dis 2001 38 2 406 408 10.1053/ajkd.2001.27007 11479170
21. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G, Am J Kidney Dis 2004 44 3 385 401 10.1053/j.ajkd.2004.05.020 15332211
22. Renal function in proteinuric glomerular diseases correlates to the changes in urine IgM excretion but not to the changes in the degree of albuminuria. Bakoush O, Torffvit O, Rippe B, Tencer J, Clin Nephrol 2003 59 5 345 352 10.5414/CNP59345 12779096
23. Urine excretion of protein HC in proteinuric glomerular diseases correlates to urine IgG but not to albuminuria. Bakoush O, Grubb A, Rippe B, Tencer J, Kidney Int 2001 60 5 1904 1909 10.1046/j.1523-1755.2001.00018.x 11703609
24. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Dussol B, Morange S, Burtey S, Indreies M, Cassuto E, Mourad G, Villar E, Pouteil-Noble C, Karaaslan H, Sichez H, Lasseur C, Delmas Y, Nogier MB, Fathallah M, Loundou A, Mayor V, Berland Y, Am J Kidney Dis 2008 52 4 699 705 10.1053/j.ajkd.2008.04.013 18585835
25. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Praga M, Barrio V, Juarez GF, Luno J, Grupo Espanol de Estudio de la Nefropatia M, Kidney Int 2007 71 9 924 930 10.1038/sj.ki.5002215 17377504
26. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Ruggenenti P, Cravedi P, Sghirlanzoni MC, Gagliardini E, Conti S, Gaspari F, Marchetti G, Abbate M, Remuzzi G, Clin J Am Soc Nephrol 2008 3 6 1652 1659 10.2215/CJN.01730408 18684896
27. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Berg AL, Nilsson-Ehle P, Arnadottir M, Kidney Int 1999 56 4 1534 1543 10.1046/j.1523-1755.1999.00675.x 10504505
28. Rituximab in idiopathic membranous nephropathy. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Marasa M, Remuzzi G, J Am Soc Nephrol 2012 23 8 1416 1425 10.1681/ASN.2012020181 22822077